Business

Spyre Therapeutics prices up USD 300m public offering

Waltham, Massachusetts-based Spyre Therapeutics, Inc. (NASDAQ: SYRE) has commenced an underwritten public offering of USD 300 million of common stock, with...

Apr 14

Hemab Therapeutics moving towards Nasdaq IPO

Hemab Therapeutics Holdings, Inc. filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission for an initial public offering of...

Seaport Therapeutics files to for Nasdaq listing to support oral psychiatric therapies

Seaport Therapeutics filed an S-1 registration statement with the SEC for an initial public offering of common stock on the Nasdaq Global Market under the...

Everest acquires Hasten Biopharmaceuticals' Asia-Pacific platform for USD 250m

Everest Medicines Acquires Asia Pacific Commercial Platform for USD 250 Million via Hasten Biopharmaceuticals Deal

Haisco Pharma hands novel pain compound portfolio to AbbVie for USD 745m

A portfolio of novel pain compounds developed by Haisco Pharmaceutical Group (SZSE: 002653) has been licensed exclusively to AbbVie (NYSE: ABBV) under an...

Marvel Biosciences secures non-dilutive funding from 5 Horizons Ventures for MB-204 trial

Calgary-based Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) has secured non-dilutive financial and strategic support from 5 Horizons Ventures to fund...

Annovis Bio closes USD 10m offering to fund Phase III Alzheimer's disease trial

Annovis Bio, Inc. (NYSE: ANVS), a Malvern, Pennsylvania-based clinical-stage company developing oral therapies for neurodegenerative disease, has closed a...

Sino-US biotech Vivatides closes USD 54m Series A for extrahepatic RNA therapeutics

Vivatides Therapeutics, a biotechnology company with operations in Woburn, Massachusetts and Suzhou, China focused on extrahepatic RNA-targeting...

Avalyn Pharma files for Nasdaq IPO to advance inhaled pulmonary fibrosis therapies

Avalyn Pharma Inc. filed for an initial public offering on the Nasdaq Global Market under the ticker symbol AVLN, according to an S-1 registration statement...

China's Oricell closes USD 110 million pre-IPO financing for CAR-T pipeline

Shanghai-based Oricell Therapeutics Holdings Limited has closed a pre-IPO financing round in excess of USD 110 million to advance its CAR-T cell therapy...

Click Therapeutics closes USD 50m Series D led by Boehringer for prescription digital device

New York-based Click Therapeutics has closed a Series D round anchored by a USD 50 million strategic investment from Boehringer Ingelheim, alongside...

Gilead licenses Kymera's oral CDK2 molecular glue degrader KT-200 for USD 45m milestone

KT-200, an oral CDK2 molecular glue degrader discovered by Kymera Therapeutics (NASDAQ: KYMR), has moved closer to the clinic after Gilead Sciences (NASDAQ:...

Shionogi secures USD 482 million BARDA Project BioShield contract for Fetroja

Shionogi's New Jersey subsidiary has secured a contract through BARDA's Project BioShield program worth an initial USD 119 million, with multiyear options...

Basilea receives USD 6 million CARB-X funding for BAL2420 antibiotic development

Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company headquartered in Allschwil, Switzerland, has received an additional USD...